An Eight-Week, Randomized, Double-Blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 06 Nov 2012 Planned number of patients (846) added as reported by European Clinical Trials Database.
- 10 May 2011 New source from European Clinical Trials Database identified (EudraCT2004-001062-40) and integrated.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History